ENDPOINTS NEWS l Shanghai- and San Francisco-based MicuRx has filed an IPO on the Hong Kong stock exchange to raise funds to advance its antibiotic contezolid acefosamil MRX-4 program, and also invest further in its CARB-X-backed preclinical polymicin antibiotic project.